NextCure, Inc. (NXTC) Stock

NextCure, Inc. (NXTC) is a Healthcare stock trading at $6.37 (as of 2026-08-21), with a market capitalization of $29.16M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines aimed at treating cancer and other immune-related diseases. Its pipeline includes NC318 in Phase II for advanced or metastatic solid tumors, NC410 in Phase I, and other candidates such as NC762 and NC525.

Valuation — source: SEC EDGAR (first-party)
Price$6.37
Market Cap$29.16M
Price / Book2.40
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$22.38M
Net Margin-163.6%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSquadron Capital Management LLC ($2.83M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMichael S. Richman
Employees43
CountryUS
IPO Date2019-05-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Actuate Therapeutics Inc (ACTU)
  • IGC Pharma, Inc. (IGC)
  • Lantern Pharma Inc. (LTRN)
  • Daré Bioscience, Inc. (DARE)
  • BeyondSpring Inc. (BYSI)
  • NanoViricides, Inc. (NNVC)
  • Optimi Health Corp. (OPTH)
  • BioXcel Therapeutics, Inc. (BTAI)
NXTC earnings history · NXTC institutional & insider holders · NXTC KPIs & operating metrics · NXTC financials · NXTC investor presentations & press releases · NXTC SEC filings · NXTC peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.